Cara Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus.
STAMFORD, Conn., Dec. 03, 2019 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Company presentation at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 3:00 p.m. ET in New York, NY.
